SCHEMBL18201219

SCHEMBL18201219

c1ccc(-c2cc(-c3ccccc3)nc(-c3cnc(-c4nc5ccccc5c5c4ccc4ccccc45)c4ccccc34)n2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.43
HPGD P15428 4/20 0.43
MAPT P10636 3/20 0.43
ALDH1A1 P00352 2/20 0.43
SMN1; SMN2 Q16637 5/20 0.39
LMNA P02545 4/20 0.39
NPC1 O15118 1/20 0.39
RECQL P46063 1/20 0.39
RAB9A P51151 1/20 0.39
TSHR P16473 1/20 0.39
MAPK1 P28482 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ACHE P22303 1/20 0.38
PTGES O14684 1/20 0.37
NQO2 P16083 1/20 0.36
PDE10A Q9Y233 1/20 0.35
TOP1 P11387 1/20 0.35
L3MBTL1 Q9Y468 2/20 0.35
ACACA Q13085 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18201223 0.93 MAPT (0.42) KDM4EHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL18200703 0.91 MAPT (0.40) KDM4EHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL18200706 0.91 MAPT (0.40) KDM4EHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL18200697 0.91 MAPT (0.40) KDM4EHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL18200805 0.90 KDM4E (0.43) KDM4EHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL18201218 0.90 MAPT (0.43) KDM4EHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL18201254 0.88 MAPT (0.42) KDM4EHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL18347071 0.88 MAPT (0.42) KDM4EHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL18200705 0.87 MAPT (0.41) KDM4EHPGDMAPTALDH1A1SMN1; SMN2
SCHEMBL18201271 0.86 MAPT (0.40) KDM4EHPGDMAPTALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-9728731-B2 Heterocyclic compound and organic light emitting device using same HEESUNG MATERIAL LTD. (KR) 2017-08-08 US disclosed
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME HEESUNG MATERIAL LTD. (KR) 2016-12-29 US disclosed
EP-3088392-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME Heesung Material Ltd. (KR) 2016-11-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160380208-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING DEVICE USING SAME NOTUM, DDT, CRY1 KDM4E 1977/4885HPGD 421/4885MAPT 1937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.